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Background: Nanosilver is used in a variety of medical and consumer products because of its antibacterial activity.
This wide application results in an increased human exposure. Knowledge on the systemic toxicity of nanosilver is,
however, relatively scarce. In a previous study, the systemic toxicity of 20 nm silver nanoparticles (Ag-NP) was
studied in a 28-day repeated-dose toxicity study in rats. Ag-NP were intravenously administered with a maximum
dose of 6 mg/kg body weight (bw)/day. Several immune parameters were affected: reduced thymus weight,
increased spleen weight and spleen cell number, a strongly reduced NK cell activity, and reduced IFN-γ production
were observed.
Methods: Prompted by these affected immune parameters, we wished to assess exposure effects on the functional
immune system. Therefore, in the present study the T-cell dependent antibody response (TDAR) to keyhole limpet
hemocyanin (KLH) was measured in a similar 28-day intravenous repeated-dose toxicity study. In addition, a range
of immunological parameters was measured. Data obtained using the benchmark dose (BMD) approach were
analyzed by fitting dose-response models to the parameters measured.
Results: A reduction in KLH-specific IgG was seen, with a lowest 5% lower confidence bound of the BMD (BMDL)
of 0.40 mg/kg bw/day. This suggests that Ag-NP induce suppression of the functional immune system. Other
parameters sensitive to Ag-NP exposure were in line with our previous study: a reduced thymus weight with a
BMDL of 0.76 mg/kg bw/day, and an increased spleen weight, spleen cell number, and spleen cell subsets, with
BMDLs between 0.36 and 1.11 mg/kg bw/day. Because the effects on the spleen are not reflected by increased
KLH-specific IgG, they, however, do not suggest immune stimulation.
Conclusions: Intravenous Ag-NP administration in a 28-day repeated-dose toxicity study induces suppression of the
functional immune system. This finding underscores the importance to study the TDAR to evaluate immunotoxicity
and not to rely solely on measuring immune cell subsets.
Keywords: Nanosilver, Repeated-dose toxicity, T-cell dependent antibody response, Keyhole limpet hemocyanin,
Benchmark dose, ImmunosuppressionBackground
Silver nanoparticles (Ag-NP) are frequently used in con-
sumer and medical products because of their antimicrobial
activity [1-5]. Despite the increased use of nanosilver-
containing products [5-7], there is only limited information
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ation 13-week repeated-dose exposure studies did not
show severe systemic toxicity of nanosilver [8-13]. This
is probably because of the relatively low systemic expos-
ure to nanosilver that is due to its low absorption from
the gastro-intestinal tract (GI-tract) and lungs. However,
clinical chemistry showed an increase in alkaline phos-
phatase (ALP), aspartate aminotransferase (ALT), and
cholesterol, indicating liver toxicity [9,11,13]. Moreover,tral Ltd. This is an Open Access article distributed under the terms of the
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performed a 28-day repeated-dose toxicity study [14] in
which nanosilver was administered intravenously. This
exposure route was chosen in order to avoid the limited
systemic exposure due to the cellular barriers present in
the GI-tract and lungs. Several immune parameters were
affected: reduced thymus weight, increased spleen weight
and spleen cell number, strongly reduced NK cell activity,
and reduced IFN-γ production were observed.
A next step in the risk assessment of Ag-NP immuno-
toxicity is to evaluate exposure effects on a functional im-
mune response. Therefore, in the present study the T-cell
dependent antibody response (TDAR) to keyhole limpet
hemocyanin (KLH) was determined in an intravenous
28-day repeated-dose toxicity study. In addition, a range of
immunological parameters was measured, such as weights
of organs of the immune system, hematology parameters,
spleen cell subsets, and cytokine production.
Results
Effects of KLH immunization
KLH immunization did not affect body or organ weights.
Immunization resulted in a 2% increase in mean corpus-
cular hemoglobin (MCH) (P = 0.007), a 4% decrease in
hemoglobin distribution width (HDW) (P = 0.046), and a
17% increase in mean platelet volume (MPV) (P = 0.004).
All other red blood cell and hemoglobin parameters
were unaffected.
KLH immunization did not affect white blood cell
parameters and did not affect bone marrow (BM) cellular-
ity. Immunization did not affect spleen cell numbers, or
percentages or numbers of the spleen cell populations
analyzed (CD3, CD4, CD8, CD161a, and CD45RA).
KLH immunization resulted in a 30- to 60-fold increase
in KLH-specific IgG compared to the non-specific back-
ground level (P < 0.001 and P = 0.009 for the control and
6 mg/kg Ag-NP groups, respectively). Immunization
did not significantly increase KLH-specific IgM above
the non-specific background level.
KLH immunization did not affect cytokine production.
Effects of Ag-NP exposure
Table 1 shows for the various parameters evaluated the
benchmark response (BMR), and the benchmark dose
(BMD) with its 90% confidence interval (CI), the lowest
5% lower confidence bound (BMDL) and the highest 95%
upper confidence bound (BMDU). Since the BMDL is
considered the starting point for risk assessment [15], the
presentation of the results is according to the BMDL.
Body and organ weights
Body weight was decreased by Ag-NP exposure, with a
BMDL of 1.84 mg/kg bw/day, and thymus weight was
decreased, with a BMDL of 0.76 mg/kg. Spleen weightwas increased, with a BMDL of 0.76 mg/kg. There was
no effect of Ag-NP exposure on liver and kidney
weights. The original data are shown in Additional file
1: Table S1.
Bone marrow cellularity
No exposure effect on bone marrow (BM) cellularity
was seen. The original data are shown in Additional file
1: Table S2.
Red blood cell and hemoglobin parameters
The number of red blood cells (RBC), red cell distribu-
tion width (RDW), and hemoglobin distribution width
(HDW) were increased by Ag-NP exposure, with
BMDLs of 2.04, 1.50, and 1.28 mg/kg, respectively. Mean
corpuscular volume (MCV), mean corpuscular
hemoglobin (MCH), and mean corpuscular hemoglobin
concentration (MCHC) were decreased, with BMDLs of
1.77, 1.39, and 5.65 mg/kg, respectively. The other red
blood cell and hemoglobin parameters evaluated;
hemoglobin concentration (HGB), hematocrit (HCT),
platelet count (PLT), and mean platelet volume (MPV)
were unaffected by exposure. The original data are
shown in Additional file 1: Table S2.
White blood cell parameters
The percentages of neutrophils, monocytes, large un-
stained cells, and reticulocytes were increased by Ag-NP
exposure, with BMDLs of 0.69, 0.48, 1.24, and 0.85 mg/
kg, respectively. The number of monocytes was in-
creased, with a BMDL of 0.35 mg/kg. The percentage of
lymphocytes was decreased, with a BMDL of 2.57 mg/
kg. The percentages of eosinophils and basophils were
unaffected.
The numbers of neutrophils, lymphocytes, eosinophils,
large unstained cells, basophils, and reticulocytes were
unaffected, however, suggesting a minor effect of Ag-NP
exposure on the distribution of white blood cells. The
original data are shown in Additional file 1: Table S3.
Spleen cell populations
Spleen cell number and percentages of CD3, CD4, and
CD8 cells were increased by Ag-NP exposure, with
BMDLs of 0.74, 1.09, 1.11, and 0.73 mg/kg, respectively.
The numbers of CD3, CD4, and CD8 cells were in-
creased, with BMDLs of 0.45, 0.46, and 0.39 mg/kg,
respectively.
The percentage and number of CD161a cells was in-
creased, with BMDLs of 0.62 and 0.36 mg/kg, respect-
ively. The percentage of CD45RA cells was unaffected
by exposure, while the number of CD45RA cells was in-
creased, with a BMDL of 0.68 mg/kg. The CD3/CD45RA
ratio was increased, with a BMDL of 0.86 mg/kg. The
original data are shown in Additional file 1: Table S4.
Table 1 Summary of BMDs BMR, benchmark response; BMD, benchmark dose; CI, 90% confidence interval, with BMDL
(lowest 5% lower confidence bound) and BMDU (highest 95% upper confidence bound) indicated; statistical model: 2
(E2/H2), 3 (E3/H3), and 5 (E5/H5)
Parameter BMR (5%) BMD (mg/kg bw, day) CI (5% - 95%) Statistical model
Body weight ↓ 2.85 1.84 – 5.72 2
Spleen weight ↑ 0.98 0.76 – 1.28 2
Thymus weight ↓ 1.31 0.76 – 3.03 2
RBC ↑ 2.64 2.04 – 3.62 2
RDW ↑ 1.79 1.50 – 2.02 5
HDW ↑ 1.89 1.28 – 2.48 5
MCV ↓ 1.95 1.77 – 2.11 5
MCH ↓ 1.76 1.39 – 1.91 5
MCHC ↓ 7.26 5.65 – 10.2 2
% neutrophils ↑ 1.23 0.69 – 3.76 2
% lymphocytes ↓ 4.15 2.57 – 10.0 2
% monocytes ↑ 0.69 0.48 – 1.01 2
% large unstained cells ↑ 3.74 1.24 – 4.31 3
% reticulocytes ↑ 1.23 0.85 – 1.96 2
# monocytes ↑ 0.59 0.35 – 1.16 2
Spleen cell number ↑ 1.03 0.74 – 1.51 2
% CD3 ↑ 1.41 1.09 – 1.88 2
% CD4 ↑ 1.47 1.11 – 2.04 2
% CD8 ↑ 1.11 0.73 – 1.95 2
% CD161a ↑ 0.89 0.62 – 1.34 2
CD3/CD45RA ratio ↑ 1.21 0.86 – 1.85 2
# CD3 ↑ 0.63 0.45 – 0.86 2
# CD4 ↑ 0.64 0.46 – 0.88 2
# CD8 ↑ 0.57 0.39 – 0.84 2
# CD161a ↑ 0.52 0.36 – 0.72 2
# CD45RA ↑ 1.10 0.68 – 2.23 2
KLH-IgG ↓ 0.73 0.40 – 1.63 2
KLH-IgM ↑ 5.28 3.64 – 6.01 3
Thymus IL-10 ↓ 1.17 0.58 – 4.53 2
Thymus IL-17 ↓ 2.79 1.47 – 6.60 2
Spleen IL-1β ↑ 2.74 1.57 – 6.94 2
Spleen IL-6 ↑ 2.22 1.21 – 6.20 2
%, percentage; #, number
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KLH-specific IgG was decreased by Ag-NP exposure, with
a BMDL of 0.40 mg/kg. KLH-specific IgM was increased
by Ag-NP exposure, with a BMDL of 3.64 mg/kg. The
original data are shown in Additional file 1: Table S5.
Cytokine production
IL-10 and IL-17 production by Con A-stimulated thymo-
cytes were decreased by Ag-NP exposure, with a BMDL of
0.58 and 1.47 mg/kg, respectively. IL-1β and IL-6 produc-
tion by Con A-stimulated splenocytes were decreased witha BMDL of 1.57 and 1.21 mg/kg, respectively. IFN-γ, IL-2,
and TNF-α production by Con A-stimulated thymocytes,
and IL-2 and IL-10 production by Con A-stimulated sple-
nocytes were unaffected by exposure. The original data are
shown in Additional file 1: Table S6.
Comparison of BMD values
In Figure 1, the parameters measured are sorted according
to their BMDL. Among the most sensitive parameters
are the increased numbers of spleen monocytes, NK cells
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Figure 1 BMD with 90% CI. BMR = 5%. Red: increased; Green: decreased. Sorted by BMD.
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parameter. In addition, reduced KLH-specific IgG is among
the most sensitive parameters. Collectively, these findings
suggest that the number of spleen mononuclear cells and
KLH-specific IgG are the parameters that are affected after
exposure to low doses of intravenous Ag-NP.
Discussion
The present study is an extension of our previous intraven-
ous 28-day repeated dose exposure study of 20 nm Ag-NP
[14]. In the present study, and not in the previous one, the
effect on the functional immune response, being the TDAR
to KLH, was investigated. We confirm in the present study
the observations of reduced body and thymus weight,
increased spleen weight and spleen cell number, includ-
ing increased percentages and numbers of the various
spleen cell subsets measured. With the exception of thehemoglobin distribution width (HDW) which was de-
creased in our previous study, the exposure effects on
red blood cell and hemoglobin parameters are similar.
Most importantly, in the present study we show a re-
duced KLH-specific IgG response.
In our previous study [14], the most sensitive par-
ameter was reduced thymus weight, with a BMD of
0.01 mg/kg (90% CI 0.001 – 0.14 mg/kg). In the present
study a considerably higher BMD of 1.31 mg/kg (90% CI
0.76 - 3.03 mg/kg) was obtained. One explanation for
this major difference is the fact that in the present
study the animals were sacrificed 21 days after cessa-
tion of Ag NP exposure, whereas in our previous study
the animals were euthanized 24 hours after final expos-
ure. It should be mentioned that for all other parame-
ters for which BMDs were determined in both studies,
the difference in BMD between the two studies was much
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higher BMD.
Our study shows that the number of spleen mononuclear
cells and KLH-specific IgG are the parameters that are
affected after exposure to low doses of intravenous Ag-NP.
The increased number of spleen mononuclear cells sug-
gests immunostimulation, while reduced KLH-specific
IgG suggests immunosuppression. Importantly, reduc-
tion of KLH-specific IgG suggests suppression of the
functional immune system, leading to e.g. reduced resist-
ance to infections by bacteria and viruses. As such, this
observation of reduced KLH-specific IgG should be given
more emphasis than an increased number of mononuclear
cells in the spleen. Together with a similar KLH-specific
IgM (and an increase at a higher dose), reduced KLH-
specific IgG suggests that class switching from IgM to IgG
is prevented by Ag-NP exposure. This effect is known to
be induced by immunosuppressive drugs such as cyclo-
sporine A and FK 506 [16]. The observation of reduced
thymus weight, which is indicative for immune suppres-
sion by xenobiotics, is in line with reduced KLH-specific
IgG and may suggest that impaired T-cell function is a
cause for reduced KLH-specific IgG. Moreover, this
finding underscores the importance to study TDAR to
evaluate immunotoxicity and not to rely only on measuring
immune cell subsets.
The present study was performed according to OECD
guideline 407 (“Repeated dose 28-day oral study in rodents”)
with some adjustments. First, animals were exposed
to Ag-NP via intravenous administration. Second, the
study was performed according to the BMD approach.
Third, animals were immunized to KLH during expos-
ure. Fourth, additional tests were performed to assess
possible immunotoxic properties of Ag-NP. Fifth, only
a limited number of organs was evaluated, i.e. mainly
organs of the immune system, liver and blood.
The BMD approach has important advantages over de-
termining the no-observed-adverse-effect-levels (NOAELs)
and lowest-observed-adverse-effect-levels (LOAELs), being
the more complete use of all individual data by the BMD
approach and the fact that uncertainties about the value of
a BMD can be quantified using statistical methodology.
The advantage of dose-response modeling is that this
uncertainty is made visible, whereas using the NOAEL
it remains hidden [15].
An explicit statement on the benchmark response (BMR)
is an improvement compared with the generally unknown
response level associated with a NOAEL. However, it is
often not clear what response level (BMR) can be consid-
ered as non-adverse and this choice needs consensus
building [15]. Here we chose to use a BMR of 5% [17,18].
Wound dressings are the most likely way by which
humans are exposed intravenously to silver nanoparticles.
In patients with burns the median time to maximum silverlevels was 9 days [19]; the median maximum silver level in
serum was 56.8 μg/L. In rats 2 days after inflicting a deep
partial-thickness wound and application of nano-crystalline
chitosan wound dressing, a maximum blood silver level of
0.53 μg/g was measured [20]. This latter level is in the
range of the lowest BMDL found in our study (Figure 1).
In our preceding study [14] 6 mg/kg bw was the (only)
dose that showed some general toxicity as indicated by a
reduction in body weight and was taken as the highest dose
in the current study. A wide dose range was studied,
between 8.2 μg/kg bw, corresponding to serum silver
concentrations (57 μg/L) observed in humans after using
nanosilver in wound dressings [19], and 6 mg/kg bw.
In a previous study by our group [21], the silver concen-
trations in blood after daily exposure to 0.1 mg/kg bw for
5 days was measured. Presence in organs was observed
until day 17 after repeated exposure. Since in the present
study the doses used are higher and the period of exposure
is longer, it is likely that in the present study accumulation
of the nanoparticles did occur.
While the observed effects are due to administration of
nanosilver, it is very well possible that the mechanisms
underlying the observed effects are (in part) caused by ionic
silver. For instance, using an in vitro intestinal epithelium
coculture model, the effects of the silver nanoparticles were
likely exerted by the silver ions that are released from the
nanoparticles [22].
A TDAR is dependent on both B-cell and T-helper cell
functionality, and thereby also on the functionality of
monocytes as antigen presenting cells, thus providing a
read-out that evaluates the combined functionality of
these immune cells [23]. Immunoglobulin class switching
from IgM to IgG requires “help” from T-helper cells;
therefore, KLH-specific IgG rather than KLH-specific IgM
depends on the functionality of not only B-cells but also
T-helper cells. In contrast to IgM, that depends only
on B-cell activity, IgG requires “help” from T-cells and
thereby also of antigen presenting cells. Next to being
a functional parameter, another advantage of a TDAR is
that it can be extrapolated from experimental animals
to humans. Both its functional nature and its possibility
for extrapolation are important for risk assessment. A
TDAR that can be readily measured in humans is the
vaccination titer, such as to measles and hepatitis B [24].
In the ICH S8 “Immunotoxicity studies for Human
Pharmaceuticals”, an immune function study is recom-
mended. Where a specific target is not identified, an
immune function study such as the TDAR is recom-
mended. Moreover, in the EPA Health Effects Test
Guidelines “OPPTS 870.7800 Immunotoxicity” it is stated
that hematology, lymphoid organ weights and histopath-
ology alone are not sufficient to predict immunotoxicity.
In conclusion, inclusion of a TDAR in immunotoxicity
studies is of importance.
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The conclusion of the present study is that intravenous
Ag-NP suppress the functional immune system. The
possibility that the mechanisms underlying this effect
are in fact caused by ionic silver after (slow) dissolution
of the Ag-NP cannot be excluded.
Methods
Animals
Male Wistar derived WU (CRL:WI (WU)) rats, 8 weeks of
age, were obtained from Charles River. Animals were bred
under SPF conditions and barrier maintained during the ex-
periment. Drinking water and conventional feed were pro-
vided ad libitum. Husbandry conditions were maintained
according to all applicable provisions of the national laws,
Experiments on Animals Decree and Experiments on
Animals Act. The experiment was approved by an in-
dependent ethical committee (the Animal Experiments
Committee of the National Institute for Public Health
and the Environment) prior to the study.
Chemicals
20 nm BioPure citrate Ag-NP in 2 mM citrate was ob-
tained from NanoComposix, San Diego, CA, USA. The
nanoparticle characteristics are presented in Table 2.
The nanoparticles were provided sterile. The endotoxin
level was tested using the gel clot method (LAL) and found
to be < 10 IU/ml. Fatty acid tails were not detectable. The
nanoparticle dispersions were freshly prepared every week.
Experimental design
The animals were divided in 8 dose groups and were
intravenously injected in the tail vein once daily for
28 days to either Ag-NP dispersion or vehicle control
(phosphate buffer; PB). The daily doses Ag-NP were 0,
0.0082, 0.025, 0.074, 0.22, 0.67, 2, and 6 mg/kg bw.
In order to evaluate the effects of immunization, two
additional groups were included in the study. These groups
were not KLH-immunized, with one group receiving theTable 2 Characteristics of BioPure silver nanoparticles, as
provided by the manufacturer
Parameter
Size ± SD (nm) 21.0 ± 2.6
CV (%) 12.2
Size range (nm) 12.4 - 27.9
Concentration (mg/ml) 2
Number of particles (ml-1) 3.9 × 1013
Surface area per particle (nm2) 1.40 × 103
Surface area (nm2/ml) 5.49 × 1016
Zeta potential (mV) -40.8highest Ag-NP dose and the other group not receiving
Ag-NP.
Prior to and weekly during the experiment, the rats were
weighed. Individual body weights of the rats were used to
calculate the volumes to be administered. For each group,
based on the weight of the heaviest animal of that group the
dosing solution was prepared in such a way that the heaviest
animal received 1 ml dosing solution, and the other animals
in the group less than 1 ml. Dilution was in PB.
After euthanasia, body weights and the weights of liver,
kidneys, spleen, and thymus were determined.
Keyhole limpet hemocyanin immunization
KLH immunization was performed according to Tonk et al.
[25]. Two hundred μl KLH (Pierce Biochemicals; 5 mg/ml
in sterile water) was injected subcutaneously in the neck
region. The primary and secondary immunizations were
done at days 14 and 28, respectively, after starting the
Ag-NP exposure (Figure 2). Serum was collected from
blood samples obtained at day 49 and stored at -80°C
until analysis for KLH-specific IgM and IgG.
Hematology
Hematology was performed on blood samples obtained
at autopsy. Blood was collected in EDTA-coated tubes.
All hematology parameters were determined in an Advia
120 Hematology Analyzer (Siemens, Germany). These pa-
rameters were white blood cell (WBC) count, red blood cell
(RBC) count, hemoglobin (HGB), hematocrit (HCT), mean
corpuscular volume (MCV), mean corpuscular hemoglobin
(MCH), mean corpuscular hemoglobin concentration
(MCHC), red cell distribution width (RDW), hemoglobin
distribution width (HDW), platelet (PLT) count, and mean
platelet volume (MPV). In addition, the number and
percentage of neutrophils, monocytes, lymphocytes,
eosinophils, large unstained cells, basophils, and retic-
ulocytes were measured. Next, blood smears were pre-
pared for visual evaluation.
Bone marrow
Cells were collected by flushing 4 ml Impuls Cytometer
Fluid through the femur. The concentration of nucleated
cells was determined in a Coulter Counter.
Determination of spleen cell subsets
The protocol as described by Tonk et al. [25] was used.
Spleen single-cell suspensions were examined for subset
distribution by 3-color flow cytometry, using the following
mAbs: allophycocyanin-conjugated mouse anti-rat CD3
(clone 1 F4; T-cells); R-Phycoerythrin–conjugated mouse
anti-rat CD8a (clone OX-8; T-suppressor/cytotoxic cells);
fluorescein isothiocyanate–conjugated mouse anti-rat CD4
(clone OX-35; T-helper cells); FITC-conjugated mouse
anti-rat CD45RA (clone OX-33; B-cells); PE-conjugated
Day  0  7 14 21 28 35 42 49
Ag NP exposure   
KLH administration 
Autopsy    
Figure 2 Experimental design.
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Pharmingen, San Diego, CA, USA. Single-cell suspensions
were incubated with the conjugated mAbs for 30 min at
4°C in the dark. The cells were washed twice with wash
buffer (5% bovine serum albumin (BSA; Sigma) in PBS), re-
suspended in 0.1% paraformaldehyde in PBS, and analyzed
on a FACSCalibur flow cytometer (BD Biosciences, San
Diego, CA, USA). A total of 10,000 events was recorded
per sample and analyzed.
Measurement of KLH-specific IgM and IgG
The protocol as described by Tonk et al. [25] was used.
Serum samples were tested in an anti-KLH IgM or IgG
specific ELISA using mouse monoclonal IgM (purified
mouse anti-KLH IgM; BD Pharmingen) and rat monoclo-
nal IgG2a (purified rat anti-KLH IgG2a, BD Pharmingen)
for the preparation of standard curves. Flat-bottom plates
(NUNC ImmunoPlate, Maxisorb) were coated overnight at
4°C with 5 μg/ml KLH (Pierce) in carbonate-bicarbonate
buffer (0.05 M, pH 9.6; Sigma) and blocked with assay buf-
fer (0.1% Tween-20 (Sigma-Aldrich) in PBS with 1% BSA)
for 1 hour at room temperature (RT). The plates were
washed with wash solution (0.05% Tween-20 in PBS), and
diluted samples and standards were incubated for 45 min at
37°C. After washing, the plates were incubated with goat
anti-rat IgM (Pierce) or IgG (Pierce), 1:5000 and 1:3000, re-
spectively, for 30 min at 37°C. The plates were washed and
tetramethylbenzidine substrate was added and incubatedfor 10 min in the dark at RT. The reaction was stopped
with 10% (w/v) H2SO4. Optical density was measured at
490 nm using a Spectramax 190 spectrophotometer
(Molecular Devices, Sunnyvale, CA, USA).
Cell culture
The culture medium used was RPMI-1640 (Gibco, Grand
Island, NY, USA) supplemented with 10% FCS, 100 μg/ml
streptomycin, and 100 IU/ml penicillin. Cell suspensions
were made by pressing the thymuses and spleens through a
cell strainer (Falcon, Franklin Lakes, NJ, USA). Cells were
counted using a Coulter Counter (Coulter Electronics,
Luton, UK). Suspensions of thymocytes and splenocytes
were cultured at 106 cells/ml culture medium with 5 μg/ml
Concanavalin A (MP Biomedicals, Irvine, CA, USA) in
96-well tissue culture plates (Nunc, Roskilde, Denmark) for
24 hours. Culture conditions were 37°C in a humidified
atmosphere containing 5% carbon dioxide.
Cytokine measurements
Multiplex panels measuring rat IFN-γ, IL-2, IL-10, IL-17,
and TNF-α (thymocytes) and IL-1β, IL-2, IL-6, and IL-10
(splenocytes) were used. After incubation and washing steps
[26], the beads were measured on a Bio-Plex (Bio-Rad).
Statistical analysis of Ag-NP treatment
The dose-response data were analyzed using the BMD ap-
proach with PROAST software [27] (www.rivm.nl/proast).
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whole by fitting a dose-response model over the entire
dose range studied.
Having fitted a dose-response model to the data, this
curve is used to assess the BMD associated with the
BMR of 5%. The choice of the model for deriving the
BMD follows from a procedure of applying likelihood ra-
tio tests to the five members of the following two nested
families of models:
where y is any continuous endpoint and x denotes the
dose. In these models, the parameter a represents the
background response and the parameter b can be con-
sidered as the parameter reflecting the efficacy of the
chemical (or the sensitivity of the subject). First, the
likelihood ratio test was used to establish whether exten-
sion of a model by increasing the number of parameters
resulted in a statistically significant improvement of
the fit. The model that could not be significantly im-
proved was considered as the most appropriate member
(which adequately fits but does not overfit the data) within
each family. In addition, a goodness of fit test (P > 0.05)
was applied by comparing the log-likelihood of the fitted
model to that associated with the so-called “full model”.
The full model simply consists of the observed (mean)
responses at each applied dose. The model is accepted
when the log-likelihood value of the fitted model is not
significantly worse than that of the full model. Subse-
quently, the BMDs are derived from the different models
and the 90% confidence intervals (CIs) surrounding the
BMDs are calculated using the profile-likelihood method.
The BMD used in the analysis was the geometric average
of the BMDs derived for the different models. The 90% CI
surrounding this BMD comprised the BMDL and the
BMDU found for the BMD estimates derived from the
different models.
Statistical analysis of KLH immunization
Statistical analysis of KLH immunization was performed
using the independent-samples t-test (SPSS Inc., Chicago,
IL, USA). Number of animals per group = 5.Additional file
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effects on body and organ weights. Table S2. AgNP-exposure and
KLH-immunization effects on red blood cell parameters. Table S3.
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spleen cell subsets. Table S5. AgNP-exposure and KLH-immunization
effects on KLH-specific IgG and IgM. Table S6. AgNP-exposure and
KLH-immunization effects on cytokine production by thymus and spleen cells.
Abbreviations
Ag-NP: Silver nanoparticles; BM: Bone marrow cellularity; BMD: Benchmark
dose; BMDL: Lowest 5% lower confidence bound; BMDU: Highest 95% upper
confidence bound; BMR: Benchmark response; BSA: Bovine serum albumin;
bw: Body weight; CI: Confidence interval; GI-tract: Gastro-intestinal tract;
HCT: Hematocrit; HDW: Hemoglobin distribution width; HGB: Hemoglobin;
KLH: Keyhole limpet hemocyanin; MCH: Mean corpuscular hemoglobin;
MCHC: Mean corpuscular hemoglobin concentration; MCV: Mean corpuscular
volume; MPV: Mean platelet volume; PLT: Platelet count; RBC: Red blood cell
count; RDW: Red cell distribution width; RT: Room temperature; TDAR: T-cell
dependent antibody response; WBC: White blood cell count.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RJV, ICMT, LTVDV, HVL, and WDJ were involved in conception and design of
the study; LJDLFB, ERG and HWV were involved in acquisition of data; RJV,
ICMT, HVL, and WDJ were involved in analysis and interpretation of data. RJV
drafted the manuscript; HVL and WDJ critically revised the manuscript. All
authors have given final approval of the version to be published.
Acknowledgements
The study was supported by the Netherlands Food and Consumer Product
Safety Authority project V340370.
Received: 8 November 2013 Accepted: 24 April 2014
Published: 7 May 2014
References
1. Roszek B, De Jong WH, Geertsma RE: Nanotechnology in medical
applications: state-of-the-art in materials and devices. http://www.rivm.nl/
bibliotheek/rapporten/265001001.html.
2. Chen X, Schluesener HJ: Nanosilver: a nanoproduct in medical
application. Toxicol Lett 2008, 176:1–12.
3. Rai M, Yadav A, Gade A: Silver nanoparticles as a new generation of
antimicrobials. Biotechnol Adv 2009, 27:76–83.
4. Wijnhoven SWP, Peijnenburg WJGM, Herberts CA, Hagens WI, Oomen AG,
Heugens EHW, Roszek B, Bisschops J, Gosens I, Van De Meent D, Dekkers S,
De Jong WH, Van Zijverden M, Sips AJAM, Geertsma RE: Nano-silver - a
review of available data and knowledge gaps in human and
environmental risk assessment. Nanotoxicol 2009, 3:109–138.
5. Wijnhoven SWP, Dekkers S, Hagens WI, De Jong WH: Exposure to
nanomaterials in consumer products. http://www.rivm.nl/bibliotheek/
rapporten/340370001.html.
6. Dekkers S, Prud’homme De Lodder LCH, De Winter R, Sips AJAM, De Jong
WH: Inventory of consumer products containing nanomaterials. http://www.
rivm.nl/bibliotheek/rapporten/340120001.html.
7. The project on emerging nanotechnologies: Consumer products inventory of
nanotechnology products. http://www.nanotechproject.org/inventories/consumer/.
8. Ji JH, Jung JH, Kim SS, Yoon JU, Park JD, Choi BS, Chung YH, Kwon IH,
Jeong J, Han BS, Shin JH, Sung JH, Song KS, Yu IJ: Twenty-eight-day
inhalation toxicity study of silver nanoparticles in Sprague-Dawley rats.
Inhal Toxicol 2007, 19:857–871.
9. Kim YS, Kim JS, Cho HS, Rha DS, Kim JM, Park JD, Choi BS, Lim R, Chang HK,
Chung YH, Kwon IH, Jeong J, Han BS, Yu IJ: Twenty-eight-day oral toxicity,
genotoxicity, and gender related tissue distribution of silver
nanoparticles in Sprague-Dawley rats. Inhal Toxicol 2008, 20:575–583.
Vandebriel et al. Particle and Fibre Toxicology 2014, 11:21 Page 9 of 9
http://www.particleandfibretoxicology.com/content/11/1/2110. Sung JH, Ji JH, Park JD, Yoon JU, Kim DS, Jeon KS, Song MY, Jeong J, Han
BS, Han JH, Chung YH, Chang HK, Lee JH, Cho MH, Kelmann BJ, Yu IJ:
Subchronic inhalation toxicity of silver nanoparticles. Toxicol Sci 2009,
108:452–461.
11. Kim YS, Song MY, Park JD, Song KS, Ryu HR, Chung YH, Chang HK, Lee JH,
Oh KH, Kelman BJ, Hwang IK, Yu IJ: Subchronic oral toxicity of silver
nanoparticles. Part Fibre Toxicol 2010, 7:20.
12. Van Der Zande M, Vandebriel RJ, Van Doren E, Kramer E, Herrera Rivera Z,
Serrano-Rojero CS, Gremmer ER, Mast J, Peters RJB, Hollman PCH, Hendriksen
PJM, Marvin HJP, Peijnenburg AACM, Bouwmeester H: Distribution,
elimination and toxicity of silver nanoparticles and silver ions in rats after
28-day oral exposure. ACS Nano 2012, 6:7427–7442.
13. Lee JH, Kim YS, Song KS, Ryu HR, Sung JH, Park JD, Park HM, Song NW, Shin
BS, Marshak D, Ahn K, Lee JE, Yu IJ: Biopersistence of silver nanoparticles
in tissues from Sprague–Dawley rats. Part Fibre Toxicol 2013, 10:36.
14. De Jong WH, Van Der Ven LT, Sleijffers A, Park MV, Jansen EH, Van Loveren
H, Vandebriel RJ: Systemic and immunotoxicity of silver nanoparticles in
an intravenous 28 days repeated dose toxicity study in rats. Biomaterials
2013, 34:8333–8343.
15. International Programme on Chemical Safety (IPCS): Environmental Health
Criteria 239. Principles for modeling dose-response for the risk assessment of
chemicals. World Health Organization; 2009. http://whqlibdoc.who.int/
publications/2009/9789241572392_eng.pdf.
16. Thomson AW, Propper DJ, Woo J, Whiting PH, Milton JI, Macleod AM:
Comparative effects of rapamycin, FK 506 and cyclosporine on antibody
production, lymphocyte populations and immunoglobulin isotype
switching in the rat. Immunopharmacol Immunotoxicol 1993, 15:355–369.
17. Allen BC, Kavlock RJ, Kimmel CA, Faustman EM: Dose-response assessment
for developmental toxicity. II. Comparison of generic benchmark dose
estimates with no observed adverse effect levels. Fundam Appl Toxicol
1994, 23:487–495.
18. European Food Safety Authority (EFSA): Guidance of the scientific
committee on a request from EFSA on the use of the benchmark dose
approach in risk assessment. EFSA J 2009, 1150:1–72.
19. Vlachou E, Chipp E, Shale E, Wilson YT, Papini R, Moiemen NS: The safety of
nanocrystalline silver dressings on burns: a study of systemic silver
absorption. Burns 2007, 33:979–985.
20. Lu S, Gao W, Gu HY: Construction, application and biosafety of silver
nanocrystalline chitosan wound dressing. Burns 2008, 34:623–628.
21. Lankveld DP, Oomen AG, Krystek P, Neigh A, Troost-de Jong A, Noorlander
CW, Van Eijkeren JC, Geertsma RE, De Jong WH: The kinetics of the tissue
distribution of silver nanoparticles of different sizes. Biomaterials 2010,
31:8350–8361.
22. Bouwmeester H, Poortman J, Peters RJ, Wijma E, Kramer E, Makama S,
Puspitaninganindita K, Marvin HJ, Peijnenburg AA, Hendriksen PJ:
Characterization of translocation of silver nanoparticles and effects on
whole-genome gene expression using an in vitro intestinal epithelium
coculture model. ACS Nano 2011, 5:4091–4103.
23. Plitnick LM, Herzyk DJ: The T-dependent antibody response to keyhole
limpet hemocyanin in rodents. Methods Mol Biol 2010, 598:159–171.
24. Van Loveren H, Van Amsterdam JG, Vandebriel RJ, Kimman TG, Rümke HC,
Steerenberg PS, Vos JG: Vaccine-induced antibody responses as
parameters of the influence of endogenous and environmental factors.
Environ Health Perspect 2001, 109:757–764.
25. Tonk EC, De Groot DM, Penninks AH, Waalkens-Berendsen ID, Wolterbeek
AP, Slob W, Piersma AH, Van Loveren H: Developmental immunotoxicity of
methylmercury: the relative sensitivity of developmental and immune
parameters. Toxicol Sci 2010, 117:325–335.
26. Vandebriel RJ, Gremmer ER, Vermeulen JP, Hellwig SM, Dormans JA, Roholl
PJ, Mooi FR: Lung pathology and immediate hypersensitivity in a mouse
model after vaccination with pertussis vaccines and challenge with
Bordetella pertussis. Vaccine 2007, 25:2346–2360.
27. Slob W: Dose-response modeling of continuous endpoints. Toxicol Sci
2002, 66:298–312.
doi:10.1186/1743-8977-11-21
Cite this article as: Vandebriel et al.: Immunotoxicity of silver
nanoparticles in an intravenous 28-day repeated-dose toxicity study in
rats. Particle and Fibre Toxicology 2014 11:21.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
